<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076051/" ref="ordinalpos=4688&amp;ncbi_uid=3548392&amp;link_uid=PMC3076051" image-link="/pmc/articles/PMC3076051/figure/F4/" class="imagepopup">Figure 4. Modulation of vascular BK-β1 expression by Akt/FOXO-3a/FBXO <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span>.  From: Muscle-Specific F-Box Only Proteins Facilitate BK Channel ?1 Subunit Down-Regulation in Vascular Smooth Muscle Cells of Diabetes Mellitus. </a></div><br /><div class="p4l_captionBody">Reduced FOXO-3a(T-32) phosphorylation with unchanged total FOXO-3a expression in STZ-induced diabetic rats (<b>A</b>) and in human CASMCs cultured with HG (<b>B</b>). 24-h treatment with 7 μmol/L LY294002 (LY) attenuated the phosphorylation of Akt and FOXO-3a, enhanced the expression of total FOXO-3a and atrogin-1, and reduced BK-β1 protein level in human CASMCs cultured with NG (<b>C</b>). Illustration showing the signaling mechanisms that underlie vascular BK-β1 down-regulation in diabetes (<b>D</b>).</div></div>